Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.
Roussel H, et al. Among authors: badoual c.
Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.
Oncoimmunology. 2017.
PMID: 28507793
Free PMC article.